Bibliographic information
GuidelineConsolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations
Year of Publication2022
Issuing InstitutionWHO
Recommendation
New
Pan-genotypic DAA-HCV treatment should be offered without delay to people with recently acquired HCV infection and ongoing risk
Recommended in favor
Strong
Certainty of evidence
Very low
Notes and Remarks
Remarks:
- Individuals with recently acquired infection must have the option to make an informed choice about starting treatment immediately or delaying treatment initiation.
- Treatment for recently acquired infection should be offered alongside additional, evidence-based interventions to reduce HCV risk and primary prevention services.